Monday , 6 February 2023

Brinzolamide (1%) Plus Timolol Maleate (0.5%) Versus Dorzolamide (2%) Plus Timolol Maleate (0.5%): A Randomized, Open-Label, Multicentric, Active-Controlled, Prospective Study

Sajid Yousuf Shehab Al-Asady1, Haider Abdulkareem Al-Janabi2, Hussein Mohammed Kadhim3, Mutaza Hasan Jaaz Alqaraghuli4, Eman Hussein Alwan5, Abdulrazaq Al Hilu6, Bakhttiar Qadir Hama Salh Aljaf7, Alla Razzaq Najim8, Mohammed Ali Hameed Hasan9, Ali Jawad Kadhim10, Shalini Kumar11, & *Shirley D’souza11, Vivek Konduskar11
1Albasirah Centre, Basrah – Alwoofod Street, Iraq
2Ibn Al Haytham Hospital, Baghdad
3Husain Mohammed Eye clinic, Opposite Ibn al Haytham Hospital Baghdad, Iraq
4Al hbubi hospital, Nasriya Alhbubi – Kanz st, Iraq
5New vision centre, Jumhoori hospital, Erbil, Iraq
6Absar center, Clinic / Najaf / Al muthana, Iraq
7Shahid Aso hospital, Dr Street medical city building, Sulamania, Iraq
8Alhbubi hospital, Shatra, Dr Street, Iraq
9Hussen city hospital, Alabbass bridge, Karbala, Iraq
10Imam Sadiq Hospital, Hilla, Iraq
11Ajanta Pharma Limited – Satellite Gazebo, B Wing, 301/302, 3rd, Extension, Chakala, Andheri Ghatkopar Link Road, Andheri (East), Mumbai – 400093, India

A B S T R A C T
Background: To evaluate the safety and efficacy of brinzolamide plus timolol maleate (BT) versus dorzolamide plus timolol maleate (DT) fixed-dose combination in primary open-angle glaucoma. Since limited comparative clinical studies have been conducted between BT and DT in the small number of Iraqi population, we have conducted this study in a larger Iraqi patient population. Methods: Patients with primary open-angle glaucoma received BT or DT, and the parameters were measured at five time points. The objective was to evaluate the change in the intraocular pressure(IOP, mmHg), tolerability, and adverse events. Results: Baseline IOP was 27.660±6.3297 for BT and 29.446±6.3148for DT in the left eye, and 27.910±7.3483for BT and 28.986±5.7688 for DT in the right eye. The reduction from baseline IOP was similar in both treatment groups, i.e., Brinzolamide (1%) plus timolol maleate (0.5%) (BT) and dorzolamide (2%) plus timolol maleate (0.5%) (DT) [P=0.227 (left eye) and P=0.144 (right eye)]. However, patient tolerability was better for BT with lesser ocular discomfort, pain, and blurring at the 3-month follow-up. The VAS scores for ocular discomfort, ocular pain, and ocular blurring showed a better effect in the BT treatment group as compared to the DT treatment group. [VAS scores at final follow-up (visit 5, three months follow-up): Ocular discomfort = 0 in 28 patients (BT group) and 21 patients (DT group), ocular pain = 0 in 37 (BT group) and 34 patients (DT group), ocular blurring was 0 in 38 patients (BT group) and 32 patients (DT group)]. Conclusions: Both BT and DT effectively controlled the IOP. However, patients with BT were less likely to have ocular discomfort, pain, and blurring than patients on DT.

Keywords: Brinzolamide/timolol, dorzolamide/timolol, fixed combinations, glaucoma; intraocular pressure

Scroll To Top